# A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT00777309** · PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 167 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** ARQ 197
- **DRUG:** Erlotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00777309
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777309, "A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00777309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*